Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

Novo Nordisk A/S left open the door for additional work on its pill version of Ozempic for Alzheimer’s disease after a pair ...

Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose ...

A large new trial falls short of experts’ expectations for combating the neurodegenerative disease. But there could still be ...

Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, ...

The rise of GLP-1 drugs such as Ozempic and Mounjaro has been nothing short of meteoric. Originally developed to treat ...

I don’t feel like I’m dragging anymore.” So far, he has experienced no side effects and plans to continue microdosing as long ...

Oral semaglutide did not significantly reduce disease progression in patients with early Alzheimer disease, according to results from two phase 3 trials.

RBC upgrades Neumora, citing strong early NLRP3 obesity data and growing pipeline momentum ahead of key 2026 readouts.

Ozempic (semaglutide) is a powerful and versatile drug, offering dual benefits: controlling blood sugar in type 2 diabetes, and facilitating weight loss as a secondary effect. While its primary ...

There are improved cardiovascular outcomes associated with semaglutide therapy in patients with overweight or obesity without diabetes.